Literature DB >> 34847711

Preoperative spinopelvic hypermobility resolves following total hip arthroplasty.

Peter K Sculco1, Eric N Windsor1, Seth A Jerabek1, David J Mayman1, Ameer Elbuluk2, Aaron J Buckland3,4, Jonathan M Vigdorchik1.   

Abstract

AIMS: Spinopelvic mobility plays an important role in functional acetabular component position following total hip arthroplasty (THA). The primary aim of this study was to determine if spinopelvic hypermobility persists or resolves following THA. Our second aim was to identify patient demographic or radiological factors associated with hypermobility and resolution of hypermobility after THA.
METHODS: This study investigated patients with preoperative posterior hypermobility, defined as a change in sacral slope (SS) from standing to sitting (ΔSSstand-sit) ≥ 30°. Radiological spinopelvic parameters, including SS, pelvic incidence (PI), lumbar lordosis (LL), PI-LL mismatch, anterior pelvic plane tilt (APPt), and spinopelvic tilt (SPT), were measured on preoperative imaging, and at six weeks and a minimum of one year postoperatively. The severity of bilateral hip osteoarthritis (OA) was graded using Kellgren-Lawrence criteria.
RESULTS: A total of 136 patients were identified as having preoperative spinopelvic hypermobility. At one year after THA, 95% (129/136) of patients were no longer categorized as hypermobile on standing and sitting radiographs (ΔSSstand-sit < 30°). Mean ΔSSstand-sit decreased from 36.4° (SD 5.1°) at baseline to 21.4° (SD 6.6°) at one year (p < 0.001). Mean SSseated increased from baseline (11.4° (SD 8.8°)) to one year after THA by 11.5° (SD 7.4°) (p < 0.001), which correlates to an 8.5° (SD 5.5°) mean decrease in seated functional cup anteversion. Contralateral hip OA was the only radiological predictor of hypermobility persisting at one year after surgery. The overall reoperation rate was 1.5%.
CONCLUSION: Spinopelvic hypermobility was found to resolve in the majority (95%) of patients one year after THA. The increase in SSseated was clinically significant, suggesting that current target recommendations for the hypermobile patient (decreased anteversion and inclination) should be revisited. Cite this article: Bone Joint J 2021;103-B(12):1766-1773.

Entities:  

Keywords:  Dislocation; Functional cup anteversion; Hypermobility; Radiographs; Spinopelvic mobility; Total hip arthroplasty; hips; hypermobility; lumbar lordosis; pelvic incidence; pelvic incidence and lumbar lordosis; reoperations; sacral slope; spinopelvic tilt; total hip arthroplasty (THA)

Mesh:

Year:  2021        PMID: 34847711     DOI: 10.1302/0301-620X.103B12.BJJ-2020-2451.R2

Source DB:  PubMed          Journal:  Bone Joint J        ISSN: 2049-4394            Impact factor:   5.082


  4 in total

1.  Abnormal spinopelvic mobility as a risk factor for acetabular placement error in total hip arthroplasty using optical computer-assisted surgical navigation system.

Authors:  Seong J Jang; Jonathan M Vigdorchik; Eric W Windsor; Ran Schwarzkopf; David J Mayman; Peter K Sculco
Journal:  Bone Jt Open       Date:  2022-06

2.  CORR Insights®: Small Random Angular Variations in Pelvic Tilt and Lower Extremity Can Cause Error In Static Image-based Preoperative Hip Arthroplasty Planning: A Computer Modeling Study.

Authors:  Nicholas J Giori
Journal:  Clin Orthop Relat Res       Date:  2022-04-01       Impact factor: 4.755

3.  Abnormal Spinopelvic Motion and Spine Deformity are Associated With Native Femoral Retroversion in the Setting of Total Hip Arthroplasty.

Authors:  David G Deckey; Christian S Rosenow; Cara Lai; Zachary K Christopher; Jens T Verhey; Adam J Schwartz; Joshua S Bingham
Journal:  Arthroplast Today       Date:  2022-09-19

4.  Risk Factors for Progressive Spinal Sagittal Imbalance in the Short-Term Course after Total Hip Arthroplasty: A 3 Year Follow-Up Study of Female Patients.

Authors:  Satoshi Nagatani; Satoru Demura; Satoshi Kato; Tamon Kabata; Yoshitomo Kajino; Noriaki Yokogawa; Daisuke Inoue; Yuki Kurokawa; Motoya Kobayashi; Yohei Yamada; Masafumi Kawai; Hiroyuki Tsuchiya
Journal:  J Clin Med       Date:  2022-09-01       Impact factor: 4.964

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.